Mon panier

Human VSIG3 Protein, Fc Tag (BLI verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
VS3-H5258-100ug
$360.00
VS3-H5258-1mg (500ug X 2)
$2615.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    VSIG3, IgSF11, CXADRL1, Bt-IgSF, CT119

  • Source

    Human VSIG3, Fc Tag (VS3-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Gly 241 (Accession # Q5DX21-1).

    Predicted N-terminus: Leu 23

    Request for sequence
  • Molecular Characterization

    VSIG3 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 49.7 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    VSIG3 SDS-PAGE

    Human VSIG3, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Bioactivity-ELISA

     VSIG3 ELISA

    Immobilized Human VSIG3, Fc Tag (Cat. No. VS3-H5258) at 5 μg/mL (100 μL/well) can bind Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) with a linear range of 0.313-10 μg/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     VSIG3 SPR

    Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) Captured on CM5 chip via anti-mouse antibodies surface can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 8.87 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  •  VSIG3 SPR

    Human VSIG3, Fc Tag (Cat. No. VS3-H5258) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human B7-H5, His Tag (Cat. No. B75-H52H0) with an affinity constant of 53.4 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     VSIG3 BLI

    Loaded Human VSIG3, Fc Tag (Cat. No. VS3-H5258) on AHC Biosensor, can bind Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) with an affinity constant of 3.7 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

    Protocol
  •  VSIG3 BLI

    Loaded Biotinylated Human B7-H5, Avitag,His Tag (Cat. No. B75-H82E1) on SA Biosensor, can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 0.312 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  VSIG3 BLI

    Loaded Biotinylated Human B7-H5, Fc,Avitag (Cat. No. B75-H82F3) on SA Biosensor, can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 0.617 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is a homophilic adhesion molecule that preferentially expressed in the brain. The function of VSIG3 is to stimulate cell growth through homophilic interactions. In clinical, the VSIG3 has been reported to as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. In addition, VSIG-3 is also a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers and autoimmune disorders.

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte